Carbonic Anhydrase Inhibitors: Inhibition of Transmembrane, Tumor-Associated Isozyme IX, and Cytosolic Isozymes I and II with Aliphatic Sulfamates
- 7 November 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (25) , 5471-5477
Abstract
A series of aliphatic sulfamates and related derivatives incorporating cyclic/polycyclic (steroidal) moieties in their molecules has been synthesized and assayed as inhibitors of the zinc enzyme carbonic anhydrase (CA) and, more precisely, of the cytosolic isozymes CA I and II and the transmembrane, tumor-associated isozyme CA IX. The most potent CA I inhibitor was n-tetradecyl sulfamate and some (substituted)benzyl/phenethyl sulfamates (inhibition constants in the low micromolar range). Against CA II, low nanomolar inhibitors (0.7−3.4 nM) were n-decyl sulfamate and the (substituted)benzyl/phenethyl derivatives mentioned above. Effective CA II inhibition was also observed for the hydroxy/keto derivatives of dehydroepiandrosterone sulfamate. Efficient CA IX inhibitory properties, with inhibition constants in the range of 9−23 nM, were observed for the aliphatic sulfamates C10−C16 (with the most potent inhibitor being the n-dodecyl derivative) and the (substituted)benzyl/phenethyl sulfamates. The inhibition profile of the three investigated isozymes with this type of compound was rather different, allowing us to hope that the preparation of CA IX-selective inhibitors is possible (selectivity ratios toward hCA IX versus hCA II in the range of 5−63 has been observed for some of these compounds, whereas for the clinically used sulfonamides this parameter is in the range of 0.23−0.51). These data are critical for the design of novel antitumor therapies, mainly for hypoxic tumors that overexpress CA IX, which are nonresponsive to radiation or chemotherapy.Keywords
This publication has 13 references indexed in Scilit:
- Anticancer and Antiviral SulfonamidesCurrent Medicinal Chemistry, 2003
- Carbonic Anhydrase Inhibitors. Inhibition of Tumor-Associated Isozyme IX by Halogenosulfanilamide and Halogenophenylaminobenzolamide DerivativesJournal of Medicinal Chemistry, 2003
- Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamidesBioorganic & Medicinal Chemistry Letters, 2003
- Sulfonamides and Sulfonylated Derivatives as Anticancer AgentsCurrent Cancer Drug Targets, 2002
- Applications of carbonic anhydrase inhibitors and activators in therapyExpert Opinion on Therapeutic Patents, 2002
- Review of Estrone Sulfatase and its Inhibitors - An Important New Target Against Hormone Dependent Breast CancerCurrent Medicinal Chemistry, 2002
- Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular AspectsJNCI: Journal of the National Cancer Institute, 2001
- Carbonic anhydrase inhibitors and their therapeutic potentialExpert Opinion on Therapeutic Patents, 2000
- Fine tuning of the catalytic properties of carbonic anhydraseEuropean Journal of Biochemistry, 1990
- Reactions of polyfluoroalkyl fluorosulfates with nucleophiles: an unusual substitution at the sulfur-fluorine bondJournal of the American Chemical Society, 1984